Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion type Assertion NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_head.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion description "[We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_provenance.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion evidence source_evidence_literature NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_provenance.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion SIO_000772 14961035 NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_provenance.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion wasDerivedFrom befree-20140225 NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_provenance.
- NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_assertion wasGeneratedBy ECO_0000203 NP416780.RAodvi1QnDP5LyGl8C9x3ThGNZqvNAAW6TATqyn67jZjg130_provenance.